Bay Area biotech company, once worth $1.2 billion, lays off almost entire staff
Cargo Therapeutics is laying off nearly all its employees after ceasing drug development due to trial failures, marking a major decline for the biotech firm.
Calif. biotech company once worth $476M lays off every remaining employee
Viracta Therapeutics has ceased operations and laid off all employees after failing to secure funding and ultimately shut down its drug development program.
Bay Area biotech company, once worth $1.2 billion, lays off almost entire staff
Cargo Therapeutics is laying off nearly all its employees after ceasing drug development due to trial failures, marking a major decline for the biotech firm.
Calif. biotech company once worth $476M lays off every remaining employee
Viracta Therapeutics has ceased operations and laid off all employees after failing to secure funding and ultimately shut down its drug development program.
Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views
Stocks of major vaccine companies fell after FDA official Dr. Peter Marks resigned amidst conflicts with HHS Secretary RFK Jr. over vaccine misinformation.
Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views
Stocks of major vaccine companies fell after FDA official Dr. Peter Marks resigned amidst conflicts with HHS Secretary RFK Jr. over vaccine misinformation.
Finnish biotech firm NADMED raises 3.5M in Series A round
NADMED secures €3.5 million in funding to expand its health diagnostics technology, focused on measuring crucial metabolites associated with age-related diseases.
Finnish biotech firm NADMED raises 3.5M in Series A round
NADMED secures €3.5 million in funding to expand its health diagnostics technology, focused on measuring crucial metabolites associated with age-related diseases.
Everything to know about Vivek Ramaswamy, co-lead of the Department of Government Efficiency with Elon Musk
Vivek Ramaswamy's transition from a failed presidential bid to a key position in Trump's government highlights his rapid ascent in political influence.
Lyon-based Brenus Pharma secures 22.2M to advance cancer vaccine trials: Here's how - Silicon Canals
Brenus Pharma secures €22.2M Series A funding to advance cancer vaccine development, targeting metastatic colorectal cancer and expanding into other gastric tumors.